Oligonucloetide IMT504: Effect on Mesenchimal Stem Cells in type 1 Diabetes mouse model

GÓMEZ BUSTILLO S; BIANCHI M; BIANCHI S; BONAVENTURA MM; LUX-LANTOS V; MONTANER AD

Buenos Aires

Congreso; Annual Meeting American Society for Developmental Biology; 2019

American Society for Developmental Biology

Type 1 diabetes (T1D) is a multifactorial autoimmune disease in which insulin-producing pancreatic β cells are destroyed. it has been estimated that the disease affects 20?40 million persons worldwide. No effective clinical interventions for T1D are currently available and patients are lifelong treat with insulin. there is a consensus that new innovative approaches are urgently needed to predict, treat, and prevent T1D. Different strategies to modulate immunological response and restore β cell mass have been performed, although limited by the availability of transplants and the need for chronic immunosuppression. An exciting alternative consist in using therapeutic agents that can stimulate endogenous cells. Mesenchymal stem cells (MSCs) are multipotent cells characterized for their ability to promote immune-modulation, tissue regeneration, and homeostasis. IMT504, is the prototype of the PyNTTTTGT family of immunomodulatory oligonucleotides (ODNs) is known for their regenerative and properties and proven to be effective in lowering glycaemia in non-obese diabetic (NOD) mice. Here, we investigate its action on MSC in NOD mice model. Bone marrow MSCs from pre-diabetic and diabetic NOD mice were treated, in vitro, with different doses of IMT504. Fibroblasts colony forming units (CFU-F) that originate MSCs, viability and migration assays were assessed. In conclusion, our results showed that IMT504 exert an effect on MSC that might favor the regenerative potential and the diabetic condition.